ArticleNutrients2023
Pentadecanoic Acid (C15:0), an Essential Fatty Acid, Shares Clinically Relevant Cell-Based Activities with Leading Longevity-Enhancing Compounds.
Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 44 citations in OpenAlex.
- Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial.The Journal of nutrition · 2024Trial
- The antimicrobial potential of Fomitopsis Pinicola across multiple applications.Folia microbiologica · 2026Review
- Article
- Article
- Biomarkers of Adipose Color: A Multi-Omics Analysis Unravels the Molecular Landscape of White and Yellow Fat in Kazakh Horse.Biology · 2026Article
- Investigating the potential role of propionylcarnitine in milk pentadecanoic acid synthesis in Chinese holstein dairy cows using multi-omics analysis.BMC genomics · 2026Article
- Article
- Enriching Eggs Naturally: The Nutritional Power of Black Soldier Fly Whole Dry Larvae.Animals : an open access journal from MDPI · 2026Article
- Optimization of a fatty acid methyl ester protocol for quantification of odd- and even-chain fatty acids in yeast.AMB Express · 2026Article
- Characterization of Secondary Metabolites from the Co-culture of Trichotomospora Caesia AC-1134 and Streptoverticillium sp. AC-1375 and Evaluation of its Antioxidant Properties.Current microbiology · 2026Article
- Article
- Serum metabolic characteristics of interstitial lung disease: a potential link between endocrine aging and gut-derived metabolites.Frontiers in medicine · 2026Article
- Improvement ofFrontiers in pharmacology · 2026Article
- Ameliorative Role of EthanolicVeterinary medicine international · 2026Article
- Lipid biomarkers of habitual alcohol intake and associations with pancreatic cancer risk.Journal of the National Cancer Institute · 2026Article
- Plasma pentadecanoic acid is modestly related to cardiovascular health in CARDIA and ARIC cohorts: observational associations without evidence of causality.Frontiers in nutrition · 2026Article
- Comparative Bioactivities and Fatty Acid Composition ofLife (Basel, Switzerland) · 2025Article
- Pentadecanoic acid (C15:0) and cardiovascular disease: A narrative review.World journal of cardiology · 2025Review
- Molecular and cellular mechanisms of pentadecanoic acid.World journal of biological chemistry · 2025Review
- Integration of gut microbiome and lipid metabolism reveals the anti-cancer effects of pentadecanoic acid on bladder cancer.BMC medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Pentadecanoic acid (C15:0) is an essential odd-chain saturated fatty acid with broad activities relevant to protecting cardiometabolic, immune, and liver health. C15:0 activates AMPK and inhibits mTOR, both of which are core components of the human longevity pathway. To assess the potential for C15:0 to enhance processes associated with longevity and healthspan, we used human cell-based molecular phenotyping assays to compare C15:0 with three longevity-enhancing candidates: acarbose, metformin, and rapamycin. C15:0 (n = 36 activities in 10 of 12 cell systems) and rapamycin (n = 32 activities in 12 of 12 systems) had the most clinically relevant, dose-dependent activities. At their optimal doses, C15:0 (17 µM) and rapamycin (9 µM) shared 24 activities across 10 cell systems, including anti-inflammatory (e.g., lowered MCP-1, TNFα, IL-10, IL-17A/F), antifibrotic, and anticancer activities, which are further supported by previously published in vitro and in vivo studies. Paired with prior demonstrated abilities for C15:0 to target longevity pathways, hallmarks of aging, aging rate biomarkers, and core components of type 2 diabetes, heart disease, cancer, and nonalcoholic fatty liver disease, our results support C15:0 as an essential nutrient with activities equivalent to, or surpassing, leading longevity-enhancing candidate compounds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.